Analysis of SNP profiles in patients with major depressive disorder

S. Kõks; T. Nikopensius; K. Koido; E. Maron; S. Altmäe; E. Heinaste; K. Vabrit; V. Tammekivi; P. Hallast; A. Kurg; J. Shlik; V. Vasar; A. Metspalu; E. Vasar

doi:10.1017/S1461145705005468

Back

Analysis of SNP profiles in patients with major depressive disorder

Journal article

Open access

Peer reviewed

Analysis of SNP profiles in patients with major depressive disorder

S. Kõks, T. Nikopensius, K. Koido, E. Maron, S. Altmäe, E. Heinaste, K. Vabrit, V. Tammekivi, P. Hallast, A. Kurg, …

The International Journal of Neuropsychopharmacology, Vol.9(2), pp.167-174

2005

DOI: https://doi.org/10.1017/S1461145705005468

Files and links (2)

pdf

depressive disorder.pdfDownload View

Published (Version of Record) Open Access

url

Free to Read *No subscription requiredView

Abstract

The present study focused on 91 single-nucleotide polymorphisms (SNPs) in 21 candidate genes to find associations with major depressive disorder (MDD). In total, 160 healthy controls and 177 patients with MDD were studied. We applied arrayed primer extension (APEX) based genotyping technology followed by association and haplotype analysis. SNPs in CCKAR, DRD1, DRD2, and HTR2C genes showed nominally significant associations with MDD. None of these associations remained significant after adjustment for multiple testing. Haplotype analysis revealed CCKAR haplotypes to be associated with MDD (global p=0.004). More precisely, we found the GAGT haplotype to be associated with increased risk for MDD (OR 7.42, 95% CI 2.13–25.85, p=0.002). This haplotype effect remained significant after Bonferroni correction (p=0.04 after Bonferroni's adjustment). Altogether we were able to find some nominal associations, but due to small sample size these results should be taken as exploratory. However, the effect of GAGT haplotype on the CCKAR gene may be considered as increasing the risk for MDD.

Details

Title: Analysis of SNP profiles in patients with major depressive disorder
Authors/Creators: S. Kõks (Author/Creator) - University of Tartu
T. Nikopensius (Author/Creator) - Estonian Biocentre
K. Koido (Author/Creator) - University of Tartu
E. Maron (Author/Creator) - University of Tartu
S. Altmäe (Author/Creator) - Estonian Biocentre
E. Heinaste (Author/Creator) - Estonian Biocentre
K. Vabrit (Author/Creator) - Estonian Biocentre
V. Tammekivi (Author/Creator) - Estonian Biocentre
P. Hallast (Author/Creator) - Estonian Biocentre
A. Kurg (Author/Creator) - Estonian Biocentre
J. Shlik (Author/Creator) - University of Tartu
V. Vasar (Author/Creator) - University of Tartu
A. Metspalu (Author/Creator) - Asper Biotech (Estonia)
E. Vasar (Author/Creator) - University of Tartu
Publication Details: The International Journal of Neuropsychopharmacology, Vol.9(2), pp.167-174
Publisher: Collegium Internationale Neuropsychopharmacologicum
Identifiers: 991005544292407891
Copyright: © 2005 Collegium Internationale Neuropsychopharmacologicum
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

68 File views/ downloads

48 Record Views

45 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.195 Neuroendocrine & Intestinal Disorders; 1.195.1096 Gastrin/CCK Functions
Web Of Science research areas: Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
ESI research areas: Psychiatry/Psychology